Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leteprinim SCHEMBL358491 | 0.83 | HPRT1 (0.50) | LMNA | |
| Leteprinim SCHEMBL6935182 | 0.82 | HPRT1 (0.49) | LMNA | |
| Leteprinim SCHEMBL194355 | 0.82 | HPRT1 (0.49) | LMNA | |
| Leteprinim SCHEMBL6931317 | 0.82 | HPRT1 (0.49) | — | |
| SCHEMBL5258348 | 0.74 | TK1 (0.54) | HSD17B10USP2 | |
| SCHEMBL7689210 | 0.73 | MAPT (0.44) | LMNAALDH1A1MAPTPOLBTP53 | |
| Potassium Ion SCHEMBL27586246 | 0.72 | HSD17B10 (0.41) | HSD17B10ALDH1A1POLBSMN1; SMN2TDP1 | |
| Leteprinim SCHEMBL194354 | 0.72 | HPRT1 (0.48) | LMNAMEN1KMT2A | |
| SCHEMBL454682 | 0.70 | ALDH1A1 (0.71) | HSD17B10LMNAALDH1A1TDP1KDM4E | |
| SCHEMBL6449270 | 0.70 | CYP1A2 (0.38) | HSD17B10ALDH1A1MAPTPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024258996-A1 | OCULAR DRUG DELIVERY | BAYLOR COLLEGE OF MEDICINE (US) | 2024-12-19 | — | — | WO | claimed |
| CN-112469406-A | Use of stearic acid for preventing or treating pulmonary fibrosis | 财团法人峨山社会福祉财团 | 2021-03-09 | — | — | CN | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| US-20120276019-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | DIAMEDICA INC. (CA) | 2012-11-01 | — | — | US | claimed |
| US-20110150781-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | DIAMEDICA INC. (CA) | 2011-06-23 | — | — | US | claimed |
| EP-2320939-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | Sanomune Inc. (CA) | 2011-05-18 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2010009557-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | SANOMUNE INC. (CA) | 2010-01-28 | — | — | WO | claimed |
| JP-2006512417-A | — | — | 2006-04-13 | — | — | JP | claimed |
| CN-1753675-A | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-03-29 | — | — | CN | claimed |
| EP-1636252-A1 | STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER S DISEASE | Boehringer Ingelheim International GmbH (DE) | 2006-03-22 | — | — | EP | claimed |
| US-20060025345-A1 | Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | US | claimed |
| WO-2005113582-A1 | SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | claimed |
| EP-1585520-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2005-10-19 | — | — | EP | claimed |
| US-20050090449-A1 | Novel statine derivatives for the treatment of Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-28 | — | — | US | claimed |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | claimed |
| WO-2004101603-A1 | STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| WO-2004058258-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025345-A1 | Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease | PSEN1, PSEN2, APP | HSD17B10 1854/4885LMNA 2831/4885ALDH1A1 405/4885 |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | APP, IAPP, PSEN1 | HSD17B10 1859/4885LMNA 1190/4885ALDH1A1 1185/4885 |
| US-20050090449-A1 | Novel statine derivatives for the treatment of Alzheimer's disease | HMGCR, BACE1, PSEN2 | HSD17B10 372/4885LMNA 631/4885ALDH1A1 2680/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | HSD17B10 1633/4885LMNA 1146/4885ALDH1A1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.